NNMT抗体;NNMT Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Hela cells, Primary antibody: P04322(APEH  Antibody) at dilution 1/900, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P04322(APEH  Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of NNMT Antibody**

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, generating 1-methylnicotinamide (MNA) and S-adenosylhomocysteine. NNMT plays a key role in regulating cellular methylation balance, NAD+ metabolism, and energy homeostasis. It is highly expressed in the liver and adipose tissue, with emerging roles in obesity, cancer, and neurodegenerative diseases. Dysregulated NNMT activity is linked to metabolic disorders, tumor progression (e.g., via altering SAM levels or promoting cancer cell survival), and inflammatory conditions.

NNMT antibodies are essential tools for detecting NNMT expression and studying its biological functions. They enable applications like Western blotting, immunohistochemistry (IHC), and ELISA to assess NNMT levels in tissues or cells. Research using NNMT antibodies has revealed its overexpression in cancers (e.g., glioblastoma, colorectal carcinoma) and association with poor prognosis, positioning it as a potential therapeutic target or biomarker. Additionally, these antibodies aid in exploring NNMT's role in metabolic pathways, such as its interaction with NAD+-dependent enzymes like sirtuins.

The development of specific, high-affinity NNMT antibodies continues to advance mechanistic studies and drug discovery, particularly in targeting NNMT-related pathologies.